Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EBIT (2021 - 2025)

Historic EBIT for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to -$2.1 million.

  • HeartSciences' EBIT fell 445.18% to -$2.1 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$8.2 million, marking a year-over-year decrease of 1036.08%. This contributed to the annual value of -$8.4 million for FY2025, which is 3245.92% down from last year.
  • Per HeartSciences' latest filing, its EBIT stood at -$2.1 million for Q4 2025, which was down 445.18% from -$1.9 million recorded in Q3 2025.
  • HeartSciences' 5-year EBIT high stood at -$674446.0 for Q3 2021, and its period low was -$2.4 million during Q1 2025.
  • For the 5-year period, HeartSciences' EBIT averaged around -$1.6 million, with its median value being -$1.7 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first crashed by 11204.03% in 2022, then surged by 1917.02% in 2023.
  • HeartSciences' EBIT (Quarter) stood at -$956856.0 in 2021, then crashed by 85.49% to -$1.8 million in 2022, then increased by 11.55% to -$1.6 million in 2023, then dropped by 26.44% to -$2.0 million in 2024, then fell by 4.45% to -$2.1 million in 2025.
  • Its EBIT was -$2.1 million in Q4 2025, compared to -$1.9 million in Q3 2025 and -$1.9 million in Q2 2025.